197 related articles for article (PubMed ID: 26527314)
1. Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines.
Tsidulko AY; Matskova L; Astakhova LA; Ernberg I; Grigorieva EV
Oncotarget; 2015 Dec; 6(41):43529-39. PubMed ID: 26527314
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
3. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
4. Proteoglycans as potential microenvironmental biomarkers for colon cancer.
Suhovskih AV; Aidagulova SV; Kashuba VI; Grigorieva EV
Cell Tissue Res; 2015 Sep; 361(3):833-44. PubMed ID: 25715761
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomic analysis implicates COMMD proteins as Epstein-Barr virus targets in the BL41 Burkitt's lymphoma cell line.
Gkiafi Z; Panayotou G
J Proteome Res; 2011 Jul; 10(7):2959-68. PubMed ID: 21615174
[TBL] [Abstract][Full Text] [Related]
7. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.
Nagy N; Maeda A; Bandobashi K; Kis LL; Nishikawa J; Trivedi P; Faggioni A; Klein G; Klein E
Int J Cancer; 2002 Aug; 100(4):433-40. PubMed ID: 12115526
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch.
Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G
J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983
[TBL] [Abstract][Full Text] [Related]
9. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
[TBL] [Abstract][Full Text] [Related]
10. Expression of interleukin 10 in B lymphocytes of different origin.
Finke J; Ternes P; Lange W; Mertelsmann R; Dölken G
Leukemia; 1993 Nov; 7(11):1852-7. PubMed ID: 7694007
[TBL] [Abstract][Full Text] [Related]
11. IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV.
Klein SC; Jücker M; Abts H; Tesch H
Hematol Oncol; 1995; 13(3):121-30. PubMed ID: 7622142
[TBL] [Abstract][Full Text] [Related]
12. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
13. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097
[TBL] [Abstract][Full Text] [Related]
14. CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.
Kryworuckho M; Diaz-Mitoma F; Kumar A
Immunology; 1995 Sep; 86(1):41-8. PubMed ID: 7590880
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program.
Kozireva S; Rudevica Z; Baryshev M; Leonciks A; Kashuba E; Kholodnyuk I
Viruses; 2018 May; 10(5):. PubMed ID: 29751565
[TBL] [Abstract][Full Text] [Related]
16. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.
Leucci E; Onnis A; Cocco M; De Falco G; Imperatore F; Giuseppina A; Costanzo V; Cerino G; Mannucci S; Cantisani R; Nyagol J; Mwanda W; Iriso R; Owang M; Schurfeld K; Bellan C; Lazzi S; Leoncini L
Int J Cancer; 2010 Mar; 126(6):1316-26. PubMed ID: 19530237
[TBL] [Abstract][Full Text] [Related]
17. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
18. EBV transformation overrides gene expression patterns of B cell differentiation stages.
Siemer D; Kurth J; Lang S; Lehnerdt G; Stanelle J; Küppers R
Mol Immunol; 2008 Jun; 45(11):3133-41. PubMed ID: 18430472
[TBL] [Abstract][Full Text] [Related]
19. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
20. The LCR of EBV makes Burkitt's lymphoma endemic.
Niller HH; Salamon D; Banati F; Schwarzmann F; Wolf H; Minarovits J
Trends Microbiol; 2004 Nov; 12(11):495-9. PubMed ID: 15488390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]